Scientists at the National Cancer Institute (NCI) seek licensees or co-development partners for a multispectral detection method capable of discriminating different Molecular NanoTag components. The capacity to discriminate further increases the sensitivity of detection for NanoTag molecules. Adaptations of this technology could also apply to incorporate spectral scatter detection in other cytometric and microfluidic systems.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.
The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.
The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.
The National Cancer Institute (NCI) seeks research licensees for a process that reduces nucleic acid (RNA and DNA) degradation and improves protein integrity in tissue preserved as fixed paraffin embedded specimens.
Scientists at The National Cancer Institute (NCI) and The National Institute of Neurological Disorders and Stroke (NINDS) have invented a method of imaging glucose metabolism in vivo using MRI chemical shift imaging (CSI) experiments that relies on a simple, but robust and efficient, post-processing procedure by the higher dimensional analog of singular value decomposition, tensor decomposition. This new technology is denoising software for MRIs that significantly improves the measurement of low-intensity signals without the need for dynamic nuclear polarization (DNP). The scientists seek research co-development partners and/or licensees for their invention.
The National Cancer Institute (NCI) seeks licensees for an automated digital pathology device which integrates tissue sectioning, staining, and image acquisition. The device is compatible with high-throughput data analyses.
This invention pertains to a system for continuous observation of rodents in home-cage environments with the specific aim to facilitate the quantification of activity levels and behavioral patterns for mice housed in a commercial ventilated cage rack. The National Cancer Institute’s Radiation Biology Branch seeks partners interested in collaborative research to co-develop a video monitoring system for laboratory animals.
The National Cancer Institute (NCI) seeks licensees for humanized mice that express the human isomer of mesothelin (MSLN) in the thyroid. NCI created Bl6/TPO mice for studies of mesothelin as a target for research, diagnostic, or therapeutics involving human cancers.
National Cancer Institute (NCI) researchers have developed a novel software tool for uniform recording of Mitotic Figure (MF) counts via conventional and/or digital microscopy. With this technology, diagnostic centers can standardize electronic recording, summation, and transcription of clinical data during surgical pathology examination. NCI seeks licensing partners to further develop this application for use in diagnosis and detection of malignant cancers.
Extracellular vesicles (EVs) are lipid spheres released from cells. EVs contain proteins that can serve as diagnostic biomarkers indicating the cell state at time of release. Improved detection and phenotyping of EVs and their protein cargo could lead to better cancer diagnostic and prognostic tests, as well as improved therapeutic uses. The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a software package that performs high-throughput multi-dimensional analysis of EV biomarkers.
The National Cancer Institute (NCI) seeks research co-development opportunities and/or licensees for a new biomedical device for biopsy tissue collection and storage in a sterile, well-defined environment.